← The Lantern · New Carlisle
health · class iii

Teva Pharmaceuticals USA Inc recalls Azacitidine for Injection 100mg/vial Lyophilized Powder

The stated reason: Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay.

Illustration: a pharmacy counter with pill bottles, a blister pack and one bottle set aside
Illustration · The Lantern

Teva Pharmaceuticals USA Inc began a drug recall on July 22, 2022 whose reported distribution included Ohio. FDA

What the record shows

in Romania By: Sindan Pharma SRL For BluePoint Laboratories, NDC 68001-313-56 beginning July 22, 2022, in a drug recall whose distribution included Ohio. Results below specification. FDA graded it Class III — use is not likely to cause adverse health consequences. Quantity affected: 4162 cartons. The recall is listed as terminated. FDA

1 source

Context

This is one of 1 records of this type (Class Iii) from this source in the year preceding it. FDA

The Lantern holds 60 records from this source in total, and 2880 for New Carlisle across every source. FDA

1 source

By the numbers

  • Date of record: July 22, 2022 FDA
  • Recall number: D-1334-2022 FDA
  • Recalls in this action: 1 FDA
  • Recalling firm: Teva Pharmaceuticals USA Inc FDA
  • Product: Azacitidine for Injection 100mg/vial Lyophilized Powder, Rx Only, Mfd. in Romania By: Sindan Pharma SRL For BluePoint… FDA
  • Reason for recall: Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below… FDA
1 source
How we know this:

Assembled mechanically from the source filing and The Lantern's own record database — no AI-written prose. Every figure above appears verbatim in the cited record, which is linked on this page. FDA

Sources

The source filing

Recall numberD-1334-2022
Recalls in this action1
Recalling firmTeva Pharmaceuticals USA Inc
ProductAzacitidine for Injection 100mg/vial Lyophilized Powder, Rx Only, Mfd. in Romania By: Sindan Pharma SRL For BluePoint Laboratories, NDC 68001-313-56
Reason for recallSubpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.
ClassificationClass III — use is not likely to cause adverse health consequences
Recall typedrug
Quantity4162 cartons
StatusTerminated
Voluntary or mandatedVoluntary: Firm initiated
Initiated20220722
Reported20220817
DistributionDistributed in Ohio
Firm locationParsippany, NJ, United States
View the original at fda.gov

Published by U.S. Food and Drug Administration (openFDA). This is the agency's public filing as The Lantern received it, shown with its fields named in plain English.

More from Clark County, OHWatch records like this
“Oh, No!” Have we made an error? Report it to us here! We are eager to correct the record.